A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer (Q44030242)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

29 November 2017

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer (English)

1 reference

Europe PubMed Central

29 November 2017

phase I clinical trial

0 references

author name string

Susan F Slovin

1

1 reference

Europe PubMed Central

29 November 2017

Marissa Kehoe

2

1 reference

Europe PubMed Central

29 November 2017

Robert Durso

3

1 reference

Europe PubMed Central

29 November 2017

Celina Fernandez

4

1 reference

Europe PubMed Central

29 November 2017

William Olson

5

1 reference

Europe PubMed Central

29 November 2017

Jian P Gao

6

1 reference

Europe PubMed Central

29 November 2017

Robert Israel

7

1 reference

Europe PubMed Central

29 November 2017

Howard I Scher

8

1 reference

Europe PubMed Central

29 November 2017

Stephen Morris

9

1 reference

Europe PubMed Central

29 November 2017

language of work or name

0 references

publication date

13 December 2012

1 reference

Europe PubMed Central

29 November 2017

1 reference

Europe PubMed Central

29 November 2017

31

1 reference

Europe PubMed Central

29 November 2017

6

1 reference

Europe PubMed Central

29 November 2017

943-949

1 reference

Europe PubMed Central

29 November 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

GM-CSF gene-transduced tumor vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Protective monoclonal antibodies define maturational and pH-dependent antigenic changes in sindbis virus E1 glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Circulating tumors cells as biomarkers: progress toward biomarker qualification

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Prostate-specific membrane antigen-based therapeutics.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.096

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.11.096

1 reference

Europe PubMed Central

29 November 2017

release_6avrvj6kn5dl3deprwzgior3ju

1 reference

https://api.fatcat.wiki/v0/release/6avrvj6kn5dl3deprwzgior3ju

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44030242&oldid=2105785860"